Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29811032 | 1.00 | NCEH1 (0.46) | NCEH1LMNAPRNPRXFP1NPC1 | |
| SCHEMBL5622577 | 0.84 | MEN1 (0.45) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL28655699 | 0.83 | NCEH1 (0.48) | NCEH1LMNARXFP1NPC1RAB9A | |
| SCHEMBL12268247 | 0.83 | NCEH1 (0.46) | NCEH1LMNARXFP1NPC1RAB9A | |
| SCHEMBL2396852 | 0.82 | ALDH1A1 (0.63) | NPC1RAB9AMEN1KMT2AGAA | |
| SCHEMBL12127238 | 0.82 | LMNA (0.44) | LMNANPC1RAB9AMEN1KMT2A | |
| SCHEMBL3979975 | 0.82 | METAP2 (0.50) | RXFP1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL3564612 | 0.81 | CYP17A1 (0.42) | RXFP1HPGDALDH1A1MAPTNQO2 | |
| SCHEMBL28783343 | 0.81 | KCNQ4 (0.43) | NCEH1RXFP1AAK1 | |
| SCHEMBL3565251 | 0.80 | KDM4E (0.41) | NPC1RAB9AGAAHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114616224-A | Novel tricyclic 5-HT2Antagonists | 安娜玛有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377981-B2 | CBI derivatives subject to reductive activation | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-02-19 | — | — | US | disclosed |
| US-8017640-B2 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | UNIVERSITY OF BRADFORD (GB) | 2011-09-13 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | SCRIPPS RESEARCH INSTITUTE, THE | 2011-05-12 | — | — | US | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| WO-2009064908-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| US-20070161669-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | SCHOOL OF PHARMACY UNIVERSITY OF LONDON | 2007-07-12 | — | — | US | disclosed |
| US-7192977-B2 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | SCHOOL OF PHARMACY (GB) | 2007-03-20 | — | — | US | disclosed |
| EP-1408960-B1 | BENZ-INDOLE AND BENZO-QUINOLINE DERIVATIVES AS PRODRUGS FOR TUMOUR TREATMENT | UNIV LONDON PHARMACY (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20040138246-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | INCANTHERA LIMITED (GB) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | NCEH1 479/4885LMNA 3875/4885PRNP 4878/4885 |
| US-20070161669-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | CYP1B1, CYP1A1, RECQL | NCEH1 2147/4885LMNA 910/4885PRNP 3739/4885 |
| US-20040138246-A1 | Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment | CYP1B1, CYP1A1, UGT1A1 | NCEH1 1510/4885LMNA 1262/4885PRNP 3971/4885 |
| US-20110112163-A1 | CBI DERIVATIVES SUBJECT TO REDUCTIVE ACTIVATION | DBI, CCNI, TDO2 | NCEH1 1322/4885LMNA 1339/4885PRNP 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.